Enzymatic activity of thymidine kinases of a herpes simplex virus strains resistant to acyclovir H-phosphonates

  • A. A. Gus’kova
  • M. Yu. Skoblov
  • V. L. Andronova
  • G. A. Galegov
  • S. N. Kochetkov
  • Yu. S. Skoblov
Article
  • 43 Downloads

Abstract

Some cloned laboratory mutant strains of herpes simplex virus type I resistant to acyclovir H-phosphonate were studied. As was shown for all the clones, the mutations augmented the susceptibility to cidîfovir. Thymidine kinase of the mutant viruses partially retained the capacity to phosphorylate thymidine, but lost the capacity to phosphorylate BVDU.

Keywords

thymidine kinase herpes simplex virus type I 

Abbreviations

ACV

acyclovir or (9-[(hydroxyethyl)methyl]guanine

BVDU

E-5-(2-bromovinyl)-2′-deoxyuridine

Hp-ACV

acyclovir H-phosphonate

CDV

cidofovir

HSV-1

herpes simplex virus type 1

PFU

plaque-forming unit

References

  1. 1.
    Elion, G.B., J. Med. Virol., 1993, Suppl. 1, pp. 2–6.Google Scholar
  2. 2.
    Morfin, F. and Thouvenot, D., J. Clin. Virol., 2003, vol. 26, pp. 29–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Hill, E.L., Hunter, G.A., and Ellis, M.N., Antimicrob. Agents Chemother., 1991, vol. 35, pp. 2322–2328.PubMedGoogle Scholar
  4. 4.
    Karpenko, I.L., Jasko, M.V., Andronova, V.L., Ivanov, A.V., Kukhanova, M.K., Galegov, G.A., and Skoblov, Y.S., Nucleosides Nucleotides Nucleic Acids, 2003, vol. 22, pp. 319–328.PubMedCrossRefGoogle Scholar
  5. 5.
    Ias’ko, M.V., Ulanova, N.Yu., Andronova, V.L., Ivanov, A.V., Karpenko, I.L., Kukhanova, M.K., Galegov, G.A., and Skoblov, Yu.S., Russ. J. Bioorg. Chem., 2004, vol. 30, pp. 539–546.CrossRefGoogle Scholar
  6. 6.
    Skoblov, Y.S., Karpenko, I.L., Jasko, M.V., Kukhanova, M.K., Andronova, V.L., Galegov, G.A., Sidorov, G.V., and Myasoedov, N.F., Chem. Biol. Drug. Des., 2007, vol. 69, pp. 429–434.PubMedCrossRefGoogle Scholar
  7. 7.
    Gus’kova, A.A., Skoblov, M.Y., Korovina, A.N., Yasko, M.V., Karpenko, I.L., Kukhanova, M.K., Andronova, V.L., Galegov, G.A., and Skoblov, Y.S., Chem. Biol. Drug. Des., 2009, vol. 74, pp. 382–389.PubMedCrossRefGoogle Scholar
  8. 8.
    Naesens, L. and De Clercq, E., Herpes, 2001, vol. 8, pp. 12–16.PubMedGoogle Scholar
  9. 9.
    Suzutani, T., Saijo, M., Nagamine, M., Ogasawara, M., and Azuma, M., J. Clin. Microbiol., 2000, vol. 38, pp. 1839–1844.PubMedGoogle Scholar
  10. 10.
    Saijo, M., Suzutani, T., De Clercq, E., Niikura, M., Maeda, A., Morikawa, S., and Kurane, I., Antiviral. Res., 2002, vol. 56, pp. 253–262.PubMedCrossRefGoogle Scholar
  11. 11.
    L’vov, N.D., Andronova, V.L., Leont’eva, N.A., and Galegov, G.A., Vopr. Virusol., 1999, vol. 44, pp. 247–249.PubMedGoogle Scholar
  12. 12.
    De Clercq, E., Descamps, J., Verhelst, G., Walker, R.T., Jones, A.S., Torrence, P.F., and Shugar, D., J. Infect. Dis., 1980, vol. 141, pp. 563–574.PubMedCrossRefGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2011

Authors and Affiliations

  • A. A. Gus’kova
    • 1
  • M. Yu. Skoblov
    • 1
  • V. L. Andronova
    • 2
  • G. A. Galegov
    • 2
  • S. N. Kochetkov
    • 3
  • Yu. S. Skoblov
    • 4
  1. 1.Research Center for Medical GeneticsRussian Academy of Medical SciencesMoscowRussia
  2. 2.Ivanovskii Institute of VirologyRussian Academy of Medical SciencesMoscowRussia
  3. 3.Engelhardt Institute of Molecular BiologyRussian Academy of SciencesMoscowRussia
  4. 4.Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia

Personalised recommendations